National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 10 of 2002)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, is a comprehensive piece of legislation aimed at providing a framework for the administration of public health services across the nation. A notable aspect of this Act is the inclusion of provisions concerning the Pharmaceutical Benefits Scheme (PBS), which was introduced to address the gap in accessible and affordable medication for the Australian public. This legislative instrument, F2007B01097, under subsection 85 (2AA) of the National Health Act 1953, was developed to refine and update the list of substances covered by the PBS. By declaring certain drugs and medicinal preparations to cease being subject to Part VII of the Act, the policy objective is to ensure the PBS remains efficient and responsive to contemporary healthcare needs, thereby maintaining the balance between cost-effectiveness and public health benefits.

Scope and Application

The Pharmaceutical Benefits Declaration under subsection 85 (2AA) of the National Health Act 1953 applies to the specified drugs and medicinal preparations listed in the Schedule, which include Alprostadil, Aurothioglucose, Bismuth Subcitrate and Metronidazole and Tetracycline Hydrochloride (buffered), Ergotamine Tartrate, Methenolone Acetate, Phenelzine Sulfate, and Tolbutamide. This legislative instrument affects the entities and persons involved in the pharmaceutical industry, particularly those that manufacture, supply, or dispense these medications. By removing these drugs from the coverage under Part VII of the National Health Act 1953, the Declaration alters the scope of pharmaceutical benefits available to patients and providers. The Declaration operates on a Commonwealth level, aligning with the overarching framework of the National Health Act 1953, which provides a national standard for health-related legislation across Australia. There are no stated exclusions or exemptions within this specific legislative instrument, but its effects are limited to the enumerated drugs, thereby excluding other pharmaceutical products not listed in the Schedule. Any further delineation or regulation pertaining to the application of this Declaration may be addressed through subordinate instruments issued under the authority of the National Health Act 1953.

Key Provisions

The key operative sections of this legislative instrument are subsection 85(2AA) and subsection 85(2AB) of the National Health Act 1953, which empower the Minister for Health and Ageing to make a declaration regarding the cessation of pharmaceutical benefits for specified drugs and medicinal preparations. Brett Anthony Lennon, as the Assistant Secretary of the Pharmaceutical Benefits Branch and a delegate of the Minister, has issued a Declaration under subsection 85(2AA) after consulting with the Pharmaceutical Benefits Advisory Committee as required by subsection 85(2AB). This Declaration, which took effect on 1 August 2002, specifies that the drugs and medicinal preparations listed in the Schedule will no longer be covered under Part VII of the National Health Act 1953. The Act imposes specific obligations on the entities it governs, including the Minister for Health and Ageing, who must consult with the Pharmaceutical Benefits Advisory Committee before making such a declaration. Brett Anthony Lennon, as the delegate of the Minister, must follow the statutory requirements to ensure that the consultation process is adhered to and that the declaration is made in accordance with the Act. Additionally, the Pharmaceutical Benefits Advisory Committee is obligated to provide advice to the Minister that is considered in making the declaration. Failure to comply with the provisions of the National Health Act 1953, including the failure to adhere to the requirements for making a declaration under subsection 85(2AA), may result in various legal consequences. While the specific offences, penalties, or civil/criminal consequences for non-compliance with this particular declaration are not detailed in the text, breaches of the Act generally can lead to penalties under the relevant sections of the Act. These can include fines, imprisonment, or other civil and criminal penalties as prescribed by the legislation. The precise penalties would depend on the nature and severity of the breach.